CEACAM-7: A predictive marker for rectal cancer recurrence

Craig A. Messick, Julian Sanchez, Kathryn L. DeJulius, Jeffrey Hammel, Hemant Ishwaran, Matthew F. Kalady

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Background: The identification of rectal cancer patients predisposed to developing recurrent disease could allow directed adjuvant therapy to improve outcomes while decreasing unnecessary morbidity. This study evaluates carcinoembryonic antigen cellular adhesion molecule-7 (CEACAM-7) expression in rectal cancer as a predictive recurrence factor. Methods: A single-institution colorectal cancer database and a frozen tissue biobank were queried for rectal cancer patients. CEACAM-7 messenger RNA (mRNA) expression from normal rectal mucosa and rectal cancers was analyzed using quantitative real-time polymerase chain reaction (PCR). Expression-level differences among normal tissue, disease-free survivors, and those that developed recurrence were analyzed. Results: Eighty-four patients were included in the study, which consisted of 37 patients with nonrecurrent disease (median follow-up, 170 months), 29 patients with recurrent disease, and 18 patients with stage IV disease. CEACAM-7 expression was decreased 21-fold in rectal cancers compared with normal mucosa (P = .002). The expression levels of CEACAM-7 were relatively decreased in tumors that developed recurrence compared with nonrecurrence, significantly for stage II patients (14-fold relative decrease, P = .002). For stages I-III, disease-free survival segregates were based on relative CEACAM-7 expression values (P = .036), specifically for stage II (P = .018). Conclusion: CEACAM-7 expression is significantly decreased in rectal cancer. Expression differences between long-term survivors and those with recurrent disease introduce a potential tumor marker to define a subset of patients who benefit most from adjuvant therapy.

Original languageEnglish
Pages (from-to)713-719
Number of pages7
JournalSurgery
Volume147
Issue number5
DOIs
StatePublished - May 1 2010
Externally publishedYes

Fingerprint

Carcinoembryonic Antigen
Rectal Neoplasms
Recurrence
Survivors
Mucous Membrane
Tumor Biomarkers
Disease-Free Survival
Real-Time Polymerase Chain Reaction
Colorectal Neoplasms
Databases
Morbidity
Messenger RNA
Therapeutics

ASJC Scopus subject areas

  • Surgery

Cite this

Messick, C. A., Sanchez, J., DeJulius, K. L., Hammel, J., Ishwaran, H., & Kalady, M. F. (2010). CEACAM-7: A predictive marker for rectal cancer recurrence. Surgery, 147(5), 713-719. https://doi.org/10.1016/j.surg.2009.10.056

CEACAM-7 : A predictive marker for rectal cancer recurrence. / Messick, Craig A.; Sanchez, Julian; DeJulius, Kathryn L.; Hammel, Jeffrey; Ishwaran, Hemant; Kalady, Matthew F.

In: Surgery, Vol. 147, No. 5, 01.05.2010, p. 713-719.

Research output: Contribution to journalArticle

Messick, CA, Sanchez, J, DeJulius, KL, Hammel, J, Ishwaran, H & Kalady, MF 2010, 'CEACAM-7: A predictive marker for rectal cancer recurrence', Surgery, vol. 147, no. 5, pp. 713-719. https://doi.org/10.1016/j.surg.2009.10.056
Messick CA, Sanchez J, DeJulius KL, Hammel J, Ishwaran H, Kalady MF. CEACAM-7: A predictive marker for rectal cancer recurrence. Surgery. 2010 May 1;147(5):713-719. https://doi.org/10.1016/j.surg.2009.10.056
Messick, Craig A. ; Sanchez, Julian ; DeJulius, Kathryn L. ; Hammel, Jeffrey ; Ishwaran, Hemant ; Kalady, Matthew F. / CEACAM-7 : A predictive marker for rectal cancer recurrence. In: Surgery. 2010 ; Vol. 147, No. 5. pp. 713-719.
@article{5c0f10ac02b94a0c8ec380f6c5d31e23,
title = "CEACAM-7: A predictive marker for rectal cancer recurrence",
abstract = "Background: The identification of rectal cancer patients predisposed to developing recurrent disease could allow directed adjuvant therapy to improve outcomes while decreasing unnecessary morbidity. This study evaluates carcinoembryonic antigen cellular adhesion molecule-7 (CEACAM-7) expression in rectal cancer as a predictive recurrence factor. Methods: A single-institution colorectal cancer database and a frozen tissue biobank were queried for rectal cancer patients. CEACAM-7 messenger RNA (mRNA) expression from normal rectal mucosa and rectal cancers was analyzed using quantitative real-time polymerase chain reaction (PCR). Expression-level differences among normal tissue, disease-free survivors, and those that developed recurrence were analyzed. Results: Eighty-four patients were included in the study, which consisted of 37 patients with nonrecurrent disease (median follow-up, 170 months), 29 patients with recurrent disease, and 18 patients with stage IV disease. CEACAM-7 expression was decreased 21-fold in rectal cancers compared with normal mucosa (P = .002). The expression levels of CEACAM-7 were relatively decreased in tumors that developed recurrence compared with nonrecurrence, significantly for stage II patients (14-fold relative decrease, P = .002). For stages I-III, disease-free survival segregates were based on relative CEACAM-7 expression values (P = .036), specifically for stage II (P = .018). Conclusion: CEACAM-7 expression is significantly decreased in rectal cancer. Expression differences between long-term survivors and those with recurrent disease introduce a potential tumor marker to define a subset of patients who benefit most from adjuvant therapy.",
author = "Messick, {Craig A.} and Julian Sanchez and DeJulius, {Kathryn L.} and Jeffrey Hammel and Hemant Ishwaran and Kalady, {Matthew F.}",
year = "2010",
month = "5",
day = "1",
doi = "10.1016/j.surg.2009.10.056",
language = "English",
volume = "147",
pages = "713--719",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - CEACAM-7

T2 - A predictive marker for rectal cancer recurrence

AU - Messick, Craig A.

AU - Sanchez, Julian

AU - DeJulius, Kathryn L.

AU - Hammel, Jeffrey

AU - Ishwaran, Hemant

AU - Kalady, Matthew F.

PY - 2010/5/1

Y1 - 2010/5/1

N2 - Background: The identification of rectal cancer patients predisposed to developing recurrent disease could allow directed adjuvant therapy to improve outcomes while decreasing unnecessary morbidity. This study evaluates carcinoembryonic antigen cellular adhesion molecule-7 (CEACAM-7) expression in rectal cancer as a predictive recurrence factor. Methods: A single-institution colorectal cancer database and a frozen tissue biobank were queried for rectal cancer patients. CEACAM-7 messenger RNA (mRNA) expression from normal rectal mucosa and rectal cancers was analyzed using quantitative real-time polymerase chain reaction (PCR). Expression-level differences among normal tissue, disease-free survivors, and those that developed recurrence were analyzed. Results: Eighty-four patients were included in the study, which consisted of 37 patients with nonrecurrent disease (median follow-up, 170 months), 29 patients with recurrent disease, and 18 patients with stage IV disease. CEACAM-7 expression was decreased 21-fold in rectal cancers compared with normal mucosa (P = .002). The expression levels of CEACAM-7 were relatively decreased in tumors that developed recurrence compared with nonrecurrence, significantly for stage II patients (14-fold relative decrease, P = .002). For stages I-III, disease-free survival segregates were based on relative CEACAM-7 expression values (P = .036), specifically for stage II (P = .018). Conclusion: CEACAM-7 expression is significantly decreased in rectal cancer. Expression differences between long-term survivors and those with recurrent disease introduce a potential tumor marker to define a subset of patients who benefit most from adjuvant therapy.

AB - Background: The identification of rectal cancer patients predisposed to developing recurrent disease could allow directed adjuvant therapy to improve outcomes while decreasing unnecessary morbidity. This study evaluates carcinoembryonic antigen cellular adhesion molecule-7 (CEACAM-7) expression in rectal cancer as a predictive recurrence factor. Methods: A single-institution colorectal cancer database and a frozen tissue biobank were queried for rectal cancer patients. CEACAM-7 messenger RNA (mRNA) expression from normal rectal mucosa and rectal cancers was analyzed using quantitative real-time polymerase chain reaction (PCR). Expression-level differences among normal tissue, disease-free survivors, and those that developed recurrence were analyzed. Results: Eighty-four patients were included in the study, which consisted of 37 patients with nonrecurrent disease (median follow-up, 170 months), 29 patients with recurrent disease, and 18 patients with stage IV disease. CEACAM-7 expression was decreased 21-fold in rectal cancers compared with normal mucosa (P = .002). The expression levels of CEACAM-7 were relatively decreased in tumors that developed recurrence compared with nonrecurrence, significantly for stage II patients (14-fold relative decrease, P = .002). For stages I-III, disease-free survival segregates were based on relative CEACAM-7 expression values (P = .036), specifically for stage II (P = .018). Conclusion: CEACAM-7 expression is significantly decreased in rectal cancer. Expression differences between long-term survivors and those with recurrent disease introduce a potential tumor marker to define a subset of patients who benefit most from adjuvant therapy.

UR - http://www.scopus.com/inward/record.url?scp=77950857698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77950857698&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2009.10.056

DO - 10.1016/j.surg.2009.10.056

M3 - Article

C2 - 20004437

AN - SCOPUS:77950857698

VL - 147

SP - 713

EP - 719

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 5

ER -